|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Apovia AG, of Martinsried, Germany, closed a EUR19 million (US$17.1 million) third-round financing led by Heidelberg Innovation. Other investors include Genavent, Societe Generale Asset Management and VCH Equity Group AG. Also participating were existing investors 3i, Global Life Science Holding II GmbH and Oxford Bioscience Partners and private individuals. Arthur Andersen Corporate Finance acted as adviser. Apovia will use the funding to validate its CorVax technology in humans and to further develop the companyEs product pipeline of preclinical and clinical candidates. Berthold Hackl of Heidelberg Innovation and Thomas Taapken of Genavent will join ApoviaEs supervisory ...